Insights from the top late-breaking trials at PCR London Valves 2024

Session comprising selected PCR London Valves 2024 Late-Breaking Trials submissions - In collaboration with EuroIntervention Journal (EIJ)

Discussants: A. Abizaid, D. Hildick-Smith, M. Joner, M. Lee, J. Wang

Anchorperson: D. Capodanno

Summary

Looking to stay ahead in transcatheter valve therapies? Don't miss out this video showcasing the most impactful late-breaking trials from PCR London Valves 2024.

Discover pivotal findings, including one-year results comparing two balloon-expandable TAVI valves, outcomes of the TRISCEND II trial for tricuspid regurgitation and groundbreaking insights on transfemoral J-Valve for chronic aortic regurgitation. Also featured are two-year data from the MiCLASP study on mitral repair, CLASP IID trial outcomes and one-year results of the Bicaval TricValve in severe tricuspid regurgitation. Watch it now!

Presentations available when logged in:

One-year results of a randomised study comparing two balloon expandable TAVI valves
30 days outcomes of transfemoral J-valve for chronic aortic regurgitation: a prospective, multicentre study in 127 cases
TRISCEND II: transcatheter valve replacement vs. medical therapy for tricuspid regurgitation
Bicaval TricValve in severe tricuspid regurgitation - One-year outcomes from the Tricbicaval registry
Two-year outcomes of mitral transcatheter edge-to-edge repair from the MiCLASP study
CLASP IID randomised trial and registry: two-year outcomes